fobrepodacin

Fobrepodacin (SPR720) is a novel oral small molecule benzimidazole prodrug developed by Spero Therapeutics for the treatment of nontuberculous mycobacterial pulmonary disease (NTM-PD). It is a phosphate ester that is rapidly converted in vivo to its active moiety, SPR719, which inhibits the ATPase activity of mycobacterial DNA gyrase B (GyrB). This mechanism is distinct from current standard-of-care antibiotics, potentially avoiding cross-resistance. In 2024, Spero Therapeutics announced the discontinuation of the SPR720 program following a Phase 2a interim analysis that failed to show efficacy differentiation from placebo and identified dose-limiting hepatotoxicity.

Other names

fobrepodacin phosphate